Anthony Evnin
Partner Emeritus @ Venrock
New York, United States
Anthony Evnin is a Series A investor at Venrock in New York focused on Biotechnology and Medical. Anthony Evnin, Ph.D. has served as a director since March 2002. He has been a Partner at Venrock, where he has focused largely on life sciences investments and, in particular, biotechnology investments, since 1975. Evnin currently serves on the boards of Infinity Pharmaceuticals, Inc. and Pharmos Corporation as well as a number of privatecompanies, including Acceleron Pharma Inc. and Metabolex, Inc. Evnin is a Trustee of The Rockefeller University, a Trustee of The Jackson Laboratory, a Trustee Emeritus of Princeton University, and a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center. Evnin holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology and an A.B. from Princeton University.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 12%
Last updated:
For AI agents: llms.txt
Industries Anthony Evnin invests in
Stages Anthony Evnin invests in
Countries Anthony Evnin invests in
Investment Focus
Industry
- Biotechnology 7 (41%)
- Medical 5 (29%)
- Pharmaceutical 5 (29%)
- Health Care 4 (24%)
- Therapeutics 3 (18%)
Stage
- Series A 4 (24%)
- Series B 4 (24%)
- Series D 2 (12%)
- Series E 2 (12%)
- Series C 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Constellation Pharmaceuticals
|
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $100M / Series F / Apr 09, 2018 | |
|
Constellation Pharmaceuticals
|
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $48.5M / Series E / Jul 01, 2017 | |
Kallyope
|
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis the communication highway between our gut and our brain offers an unprecedented opportunity to access and influence brain centers involved infundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology. | $44M / Series A / Dec 10, 2015 | |
|
Constellation Pharmaceuticals
|
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $55M / Series E / Dec 09, 2015 | |
Juno Therapeutics
|
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series Ainvestments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs. | $134M / Series B / Aug 05, 2014 | |
|
Juno Therapeutics
|
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series Ainvestments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs. | $56M / Series A / Apr 24, 2014 | |
|
Constellation Pharmaceuticals
|
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $15M / Series B / Jun 06, 2011 | |
Acceleron Pharma
|
Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone formingagent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts. | $10.3M / Jun 10, 2010 | |
|
Constellation Pharmaceuticals
|
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $22.3M / Series B / Jun 07, 2010 | |
CymaBay Therapeutics
|
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with theassets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs. | $8.6M / Series E / Nov 05, 2009 | |
| See all 17 investments → | |||
Co-Investors
About Venrock
Venrock continues a tradition of partnering with entrepreneurs to establish successful, enduring companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Endeca, Gilead Sciences, Idec Pharma, Imperva, Illumina, Intel, Nest, SlideShare,and Tudou.
Venrock Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Gottesdiener
Partner
|
|||
|
Anthony Evnin
Partner Emeritus
|
|||
Bryan Roberts
Partner
|
|||
Mariana Mihalusova
Vice President
|
|||
Mike Tyrrell
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Anthony Evnin invest in?
Anthony Evnin invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Anthony Evnin last invest?
The most recent investment recorded for Anthony Evnin closed in Oct 2007. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
